Trial Profile
Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2023
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Tuberous sclerosis
- Focus Therapeutic Use
- Sponsors Aucta Pharmaceuticals
- 28 Mar 2023 Status changed from recruiting to discontinued.
- 02 Feb 2022 Planned End Date changed from 1 Apr 2022 to 1 Mar 2023.
- 02 Feb 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.